Novo Nordisk Lowers US Prices for Wegovy, Ozempic to Reclaim Market Share

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

Novo Nordisk Slashes Wegovy, Ozempic Prices by 50% to Battle Eli Lilly

Novo Nordisk Slashes Wegovy, Ozempic Prices by 50% to Battle Eli Lilly

C

CNBC TV18•24-02-2026, 21:13

Novo Nordisk Slashes Wegovy, Ozempic Prices by 50% to Battle Eli Lilly

•Novo Nordisk plans to cut US list prices of Wegovy and Ozempic next year.
•The move aims to regain market share in the rapidly growing obesity treatment segment.
•New monthly list price for semaglutide portfolio set at $675, a reduction of up to 50%.
•This comes amid intense competition from Eli Lilly's Zepbound, priced at $1,086.37 per month.
•Price cuts could lower out-of-pocket expenses for insured patients, but won't affect self-pay prices.

Read Full Article on Cnbc in English

✦

More like this

✦

More like this

Hims & Hers Launches Cheaper Wegovy Knockoff Pill; Novo Nordisk Vows Legal Action

Hims & Hers Launches Cheaper Wegovy Knockoff Pill; Novo Nordisk Vows Legal Action

Novo Nordisk

Novo Nordisk Shares Plunge 13% as Weight-Loss Drug Fails to Match Eli Lilly Rival

Novo Nordisk

Novo Nordisk Sues Hims & Hers Over Weight-Loss Pill, Shares React

FILE PHOTO: A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. REUTERS/Hollie Adams/Brendan McDermid/Combination/File Photo

Eli Lilly stockpiles $1.5B weight-loss pill ahead of FDA decision

NMDC share price, NMDC stock, NMDC shares, NMDC, NMDC lumps price, NMDC fines price, NMDC increases prices, NMDC prices increase, NMDC price increase,

NMDC Hikes Lumps, Fines Prices by ₹100; Shares Dip Despite Revenue Surge

Representational image (Image: News18)

UGRO Capital Targets Lower Borrowing Costs by FY27: MD Sachindra Nath